Chugai Wins Taiwan Approval For PiaSky® To Treat PNH Based On Global COMMODORE Trial Data

Chugai Pharmaceutical Co., Ltd. announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval for an expanded indication of Vabysmo® Intravitreal Injection 120 mg/mL (faricimab, genetic recombination). The bispecific antibody is now approved for treating choroidal neovascularization (CNV) associated with angioid streaks, making Vabysmo the first drug approved in Japan for this rare, vision-threatening condition. 

“We are very pleased to offer Vabysmo as the first approved treatment in Japan for choroidal neovascularization associated with angioid streaks. This disease is known to cause vision impairment and has a poor prognosis. We expect that treatment with Vabysmo will contribute to maintaining and improving patient vision. We will continue to provide information promptly on the proper use of this medication,” stated Dr. Osamu Okuda, Chugai’s President and CEO.

This expanded indication is supported by data from the Japanese Phase III NIHONBASHI study, which demonstrated the safety and efficacy of Vabysmo in patients with CNV caused by angioid streaks.